SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the ...
Gene therapy ‘switch’ may offer non-addictive pain relief. New approach targets pain signals while leaving the rest of the brain untouched.
A retired HGV driver was the first person in the world to take part in a clinical trial to extend the lifespan of blood ...
John MacDonald, 73, took part in a clinical trial using gene therapy to extend the lifespan of blood vessels in the heart ...
John MacDonald, 73, agreed to take part in the study after he was rushed to the Golden Jubilee Hospital when he suffered a ...
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across ...
The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.
The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source [1]. The FDA approved three ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback